Oncology

Latest News

Insurance gaps | Image Credit: iQoncept-stock.adobe.com
Insurance Gaps Threaten Cancer Treatment Success

July 7th 2025

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com
Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

June 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Azar Announces Mandatory Oncology Payment Model Is Coming
November 8th 2018

Azar Announces Mandatory Oncology Payment Model Is Coming

Mary Caffrey Allison Inserro
The announcement is an about-face from earlier efforts that scrapped a cardiac care bundled payment program originally developed during the Obama administration.
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 8th 2018

Dr Thorvardur Halfdanarson on Diagnostics in NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses improvements in diagnostics for neuroendocrine tumors, as well as what improvements are still needed.
Immunotherapy Improves Survival in Metastatic Melanoma
November 7th 2018

Immunotherapy Improves Survival in Metastatic Melanoma

David Bai, PharmD
The use of CTLA-4, PD-1, or a combination approach achieved high response rates and improved overall survival in patients with CDKN2A mutations with metastatic melanoma, based on the results of a study by Helgadottir et al.
Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma
November 7th 2018

Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.
Hispanics Living With HIV at Increased Risk of HPV-Related Cancers
November 6th 2018

Hispanics Living With HIV at Increased Risk of HPV-Related Cancers

Jaime Rosenberg
Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 6th 2018

Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs

Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types
November 2nd 2018

Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types

Laura Joszt, MA
While survival from leukemia improved among adults from 1995 to 2009, and the survival gap between sexes decreased, the racial gap did not, according to new research published in Cancer.
New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing
November 1st 2018

New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing

Laura Joszt, MA
New guidelines released by the American Academy of Dermatology will help physicians provide the best treatment for more than 1 million Americans living with melanoma, the deadliest form of skin cancer. The guidelines also highlight the importance of discussions between physicians and patients.
Site Logo
November 1st 2018

Learnings From Priority Health's Oncology Payment Reform Model

Surabhi Dangi-Garimella, PhD
To speak about the success and continued development of Priority Health's payment reform model in cancer care, John Fox, MD, medical director at Priority Health, joined Dennis Zoet, chief business development officer at Cancer and Hematology Centers of Western Michigan, on a panel at the Community Oncology Alliance Payer Exchange Summit.
Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future
November 1st 2018

Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.
Ted Okon on Policy Priorities for COA in 2019
November 1st 2018

Ted Okon on Policy Priorities for COA in 2019

I’ve seen one case recently where a patient received $172,000 of drugs that were totally wasted. So, we’re going to be looking at this, we’re going to be looking at these middlemen getting in the way of the patient and the physician making a decision about their therapy, explained Ted Okon, executive director of COA.
Dr Lalan Wilfong Provides an Overview of Key Learnings From the OCM
November 1st 2018

Dr Lalan Wilfong Provides an Overview of Key Learnings From the OCM

Looking at total cost of care is difficult and figuring out what the practice is responsible for and not responsible for can be very difficult to do, said Lalan Wilfong, MD, executive vice president of Quality Programs at Texas Oncology.
Bo Gamble Explains How COA Defines Value in Oncology
October 31st 2018

Bo Gamble Explains How COA Defines Value in Oncology

A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values. So, [we all need to] come together, explains Bo Gamble, Director Of Strategic Practice Initiatives at the Community Oncology Alliance.
Site Logo
October 31st 2018

Experts Discuss Regulatory, Cultural Roadblocks to Progress With Value-Based Agreements

Surabhi Dangi-Garimella, PhD
At the Community Oncology Alliance Payer Exchange Summit, healthcare policy experts from a government relations firm and from the pharmaceutical industry provided an update on the progress with value-based agreements and also discussed the challenges posed by the existing infrastructure and operational framework.
The Evolution of CLL Testing and Treatment Over the Past Decade
October 30th 2018

The Evolution of CLL Testing and Treatment Over the Past Decade

Laura Joszt, MA
In the last decade, testing for and treatment of chronic lymphocytic leukemia (CLL) had undergone substantial changes with new testing that can personalize therapy and new agents that provide more clinical benefit.
Site Logo
October 30th 2018

COA's OCM 2.0: Moving Toward a Universal Payment Model

Surabhi Dangi-Garimella, PhD
The Community Oncology Alliance (COA) has been working with its member practices and some payer partners who have successfully implemented innovative care delivery and payment models to develop a 2.0 version of CMS’ Oncology Care Model (OCM). A progress report was presented at COA’s Payer Exchange Summit held October 29-30 in Tyson’s Corner, Virginia.
Site Logo
October 30th 2018

Community Practices Continue to Struggle With ED Use, Risk Stratification in OCM

Surabhi Dangi-Garimella, PhD
While practice transformation is vital, community-based clinics continue to struggle with emergency department (ED) use, hospitalization, and risk stratification as they identify ways to reduce unnecessary expenditures within their Oncology Care Model (OCM) practice.
Implications of OCM Reports and the Future of the Program
October 29th 2018

Implications of OCM Reports and the Future of the Program

Laura Joszt, MA
Lalan Wilfong, MD, moderated a conversation between Robert E. Baird, MD, CEO of Dayton Physicians Network, and Sarah Cevallos, chief revenue cycle officer for Florida Cancer Specialists and Research Institute, about current and future strategies for Oncology Care Model (OCM) participation, as well as key lessons from the OCM and how they can be applied in other reform models.
Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News
October 27th 2018

Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: October 26, 2018
October 26th 2018

This Week in Managed Care: October 26, 2018

This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.
Palbociclib Plus Fulvestrant Increases OS in HR+, HER2-Negative Breast Cancer
October 26th 2018

Palbociclib Plus Fulvestrant Increases OS in HR+, HER2-Negative Breast Cancer

Samantha DiGrande
A recent trial sought to assess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor–positive (HR+), HER2-negative advanced breast cancer.
Immunotherapy Is Safe for Patients With Cancer Living With HIV
October 25th 2018

Immunotherapy Is Safe for Patients With Cancer Living With HIV

Jaime Rosenberg
According to a study presented at the ESMO 2018 Congress in Munich, Germany, treatment with PD-1 or PD-L1 inhibitors is a feasible option for patients who have cancer and are living with HIV.
Looking Back at CAR T: PROs From a Patient's Perspective
October 23rd 2018

Looking Back at CAR T: PROs From a Patient's Perspective

A survivor of chronic lymphocytic leukemia who participated in the first chimeric antigen receptor T-cell trial in 2010 looks back at his experience and also discusses his views on how patient-reported outcomes (PROs) should be used, if at all, by CMS.
Atezolizumab Plus Chemotherapy Prolongs PFS in Triple-Negative Breast Cancer
October 23rd 2018

Atezolizumab Plus Chemotherapy Prolongs PFS in Triple-Negative Breast Cancer

Samantha DiGrande
A phase 3 trial recently investigated if nanoparticle albumin-bound paclitaxel enhances the treatment of atezolizumab in unresectable locally advanced or metastatic triple-negative breast cancer.
Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs
October 23rd 2018

Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs

It’s fair to say that the initial results of immunotherapy in neuroendocrine tumors (NETs) have been somewhat disappointing, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.
ACO Engagement With Urologists Can Reduce Overtreatment of Prostate Cancer
October 21st 2018

ACO Engagement With Urologists Can Reduce Overtreatment of Prostate Cancer

Laura Joszt, MA
Accountable care organizations (ACOs) in the Medicare Shared Savings Program vary considerably in how they treat men with newly diagnosed prostate cancer, according to a study that assessed whether the level of engagement in ACOs by urologists could affect rates of treatment, overtreatment, and spending in prostate cancer care.
One Gene Could Be Responsible for Acute Myeloid Leukemia
October 21st 2018

One Gene Could Be Responsible for Acute Myeloid Leukemia

Laura Joszt, MA
The EVI1 gene may be single-handedly at fault for acute myeloid leukemia, according to research published in Nature Communications.
Cancer Care Pathway Utilization Reduces Cost in Breast Cancer
October 20th 2018

Cancer Care Pathway Utilization Reduces Cost in Breast Cancer

Samantha DiGrande
A recent study looked to use real-world data to support the value of pathway regimens designed to create high-quality, affordable treatment in breast cancer care.
Site Logo
October 19th 2018

AJMC®tv Interviews

Laura Joszt, MA Kelly Davio
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters,AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Site Logo
October 19th 2018

From the Editor-In-Chief: Getting to The Prestige in Cancer Care

Joseph Alvarnas, MD
“Every great magic trick consists of three parts or acts. The first part is called ‘The Pledge.’ The magician shows you something ordinary. ...The second act is called ‘The Turn.’ The magician takes the ordinary something and makes it do something extraordinary. Now you’re looking for the secret, but you won’t find it, because of course you’re not really looking...Every magic trick has a third act, the hardest part, the part we call ‘The Prestige.’” — Christopher Priest, The Prestige
<1
...
363738394041424344
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo